Kato, Koji
Sugio, Takeshi
Ikeda, Takashi http://orcid.org/0000-0003-3976-5230
Yoshitsugu, Kanako
Miyazaki, Kana
Suzumiya, Junji
Yamamoto, Go
Kim, Sung-Won
Ikegame, Kazuhiro http://orcid.org/0000-0002-5421-7470
Uehara, Yasufumi
Mori, Yasuo http://orcid.org/0000-0001-6425-1720
Ishikawa, Jun
Hiramoto, Nobuhiro
Eto, Tetsuya
Nakazawa, Hideyuki
Kobayashi, Hikaru
Serizawa, Kentaro
Onizuka, Makoto http://orcid.org/0000-0003-3864-0823
Fukuda, Takahiro
Atsuta, Yoshiko http://orcid.org/0000-0003-4404-2870
Suzuki, Ritsuro http://orcid.org/0000-0002-5974-7614
Article History
Received: 30 June 2023
Revised: 6 November 2023
Accepted: 15 November 2023
First Online: 15 December 2023
Competing interests
: KK; Honoraria: Bristol-Myers Squibb, Celgene, Dainippon-Sumitomo, Janssen, Kyowa Kirin, MSD, Ono; Consulting or Advisory Role: AbbVie, AstraZeneca, Celgene, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Janssen, Novartis; Research Funding: AbbVie, MSD, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, Ono. KM; Honoraria: Chugai Pharma, SymBio Pharmaceuticals, Janssen, Eisai, Nippon Shinyaku, AstraZeneca, Bristol-Myers Squibb, Meiji Seika Pharma, Abbvie, Novartis, Incyte, Asahi Kasei; Research Funding: Eisai, Takeda, Nipoon Shinyaku, Otsuka, Chugai Pharma, Asahi Kasei, Sumitomo Dainippon Pharma Oncology, Zenyaku Kogyo. KS; Honoraria: Janssen, Sanofi, Takeda. Ritsuro Suzuki; Honoraria: Chugai, Kyowa Kirin, Takeda, Meiji Seika, Abbvie, AstraZeneca, Janssen, Otsuka, Eisai, Nippon Shinyaku, Elli Lilly, Amgen, Novartis, Nihon Kayaku, Sumitomo; Research Funding: Chugai, Kyowa Kirin, Takeda, Eisai, Shionogi, Otsuka, Taiho.